ArticleERJ open research2026
Impact of allergic bronchopulmonary aspergillosis overlap in chronic pulmonary aspergillosis.
Article in ERJ open research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Background: Chronic pulmonary aspergillosis (CPA) is a destructive fungal infection caused by Methods: We conducted a retrospective cohort study including individuals with confirmed CPA at the Royal Brompton Hospital until December 2023. Diagnoses followed ERS/ESCMID and 2024 ISHAM criteria. Demographic, clinical, microbiological and immunological data were analysed, and group comparisons performed using logistic regression and Cox proportional hazards models. Results: Among 166 individuals with CPA, 45 (27%) met ABPA diagnostic criteria. CPA/ABPA overlap was independently associated with asthma (OR 10.16) and pan-azole resistance (OR 19.37), and inversely with sarcoidosis (OR 0.22). Overall 5-year survival was 82% (84.6% in CPA alone Discussion: CPA/ABPA overlap represents a distinct clinical phenotype linked to airway disease, antifungal resistance and Th2-driven inflammation. Nutritional status and immunological activity, particularly rising
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.